IFNA1 and depressive symptom measurement: Rhesus monkeys receiving chronic (4 weeks) subcutaneous IFN-α administration showed increased anxiety-like and depression-like behaviors as well as diminished environmental exploration, accompanied by increased levels of plasma adrenocorticotropic hormone (ACTH) and cortisol, which tended to improve after the administration terminated.